argenx vs Bayer (ARGX.BR vs BAYN.DE)
argenx (ARGX.BR) vs Bayer (BAYN.DE) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
argenx (ARGX.BR) and Bayer (BAYN.DE) compete in healthcare and pharma. Here are argenx and Bayer side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy argenx or Bayer.
argenx vs Bayer: the figures
| Figure | argenx | Bayer |
|---|---|---|
| Share price | €815.00 (November 4, 2026) | €54.24 (November 4, 2026) |
| Market cap | €51.3 billion | €53.3 billion |
| P/E (TTM) | 32.8x | N/A |
| Forward P/E | 23.3x | 11.2x |
| Revenue growth (quarter) | +52.1% | +1.2% |
| Net margin (TTM) | 31.7% | -3.8% |
| Net debt / EBITDA | Net cash | 3.3x |
| Dividend yield | 0.00% | 0.22% |
| Beta | -0.07 | 0.81 |
argenx and Bayer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that argenx or Bayer figure is not available, and we never estimate it.
3 key differences between argenx and Bayer
- Growth: argenx grew sales +52.1% year on year in its latest quarter, against +1.2% for Bayer.
- Profitability: for every 100 of sales, argenx keeps 31.7 as net profit and Bayer keeps -3.8.
- Debt: Bayer owes 3.3x its annual operating profit (EBITDA), while argenx holds more cash than debt.
argenx or Bayer: which fits your profile
- If you want growth: argenx is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Bayer pays the higher dividend relative to its price.
- If you prefer caution: argenx has less debt relative to its profit, which usually gives more room in a bad year.
Neither argenx nor Bayer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How argenx and Bayer make money
argenx (ARGX.BR)
argenx is a biotech that earns its money from Vyvgart, its antibody-based treatment for autoimmune diseases such as myasthenia gravis and CIDP, sold in IV and under-the-skin forms. Nearly all sales come from this product, mostly in the US, followed by Japan and Europe, and it reinvests in research for new uses. Full argenx analysis.
Bayer (BAYN.DE)
Bayer reports three divisions: Crop Science, its largest, selling seeds (Dekalb) and crop protection to farmers; Pharmaceuticals, with prescription drugs such as Xarelto, Eylea and Nubeqa; and Consumer Health, with over-the-counter brands like Aspirin, Bepanthen and Claritin. It sells worldwide, with North America and Europe as its main markets. Full Bayer analysis.
Frequently asked questions: argenx vs Bayer
Is argenx or Bayer the better stock?
Choosing between argenx and Bayer depends on what you are looking for. argenx is growing faster right now. Fintols does not tell you whether to buy argenx or Bayer: it shows you the differences so you can decide.
Which pays a higher dividend, argenx or Bayer?
As of November 4, 2026, Bayer yields 0.22% and argenx pays none. Also check how much of their profit argenx and Bayer pay out: if it is more than they earn, it cannot last.
Can I own both argenx and Bayer?
Yes. Many people spread their money across several companies, such as argenx and Bayer, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying argenx or Bayer.
More comparisons with argenx or Bayer
More companies like argenx and Bayer: healthcare and pharma stocks. Educational content about argenx and Bayer, not investment advice.